H.C. Wainwright analyst Patrick Trucchio reiterated a Buy rating on Reunion Neuroscience (REUN – Research Report) today and set a price target of $20.00. The company’s shares closed yesterday at $1.39.
According to TipRanks, Trucchio is an analyst with an average return of -13.6% and a 33.83% success rate. Trucchio covers the Healthcare sector, focusing on stocks such as uniQure, ATAI Life Sciences, and Alnylam Pharma.
Currently, the analyst consensus on Reunion Neuroscience is a Strong Buy with an average price target of $11.69.
See today’s best-performing stocks on TipRanks >>
The company has a one-year high of $10.43 and a one-year low of $0.76. Currently, Reunion Neuroscience has an average volume of 34.53K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Field Trip is a global leader in the development and delivery of psychedelic therapies. With Field Trip Discovery, the company’s research division, leading the development of the next generation of psychedelic molecules and conducting advanced research on plant-based psychedelics, and its Field Trip Health division building centers for psychedelic therapies across North America and Europe along with the digital and technological tools that will enable massive scale.
Read More on REUN:
- Reunion Neuroscience Appoints Robert Alexander as Chief Medical Officer
- Reunion completes interim data analysis for Phase 1 trial with RE104
- Reunion Neuroscience Inc. Completes Interim Data Analysis for Phase 1 Clinical Trial with Novel Serotonergic Psychedelic RE104
- Reunion Neuroscience provides 2023 corporate update
- Reunion Neuroscience Inc. Provides 2023 Corporate Update
